Pipeline & Technology
Portfolio and pipeline
Nanovi’s liquid fiducial markers can be injected percutaneously or through endoscopes
The markers represent multimodal imaging properties to guide both radiation therapy and surgical interventions
Nanovi has 2 liquid fiducial markers :
BioXmark® is available in Europe for human use to radiographically mark soft tissue and guide high precision radiation therapy.
PetXmark™ is available in the United States to radiographically mark subcutaneous tissue in dogs and cats for high precision radiation therapy.
The pipeline comprises novel liquid markers in early development to meet unmet needs for accurate guidance of radiation therapy and surgical interventions.
Technology platform and Intellectual Property
Publication of Nanovi’s technology platform in Science Advances:
Nanovi’s products stem from a patent-protected technology platform that is co-invented and co-owned with the Technical University of Denmark – DTU. Thomas L. Andresen, professor at DTU Health Tech, Nanovi founder and board member, is the main inventor of the technology.
The platform consists of carbohydrate based biomaterial compositions to design and synthesize liquid gels for medical applications, bridging advanced diagnostic imaging techniques and therapeutic inventions. The gels allow for simple non-invasive injection, multimodality visualization and guidance of radiation therapy and surgical procedures.
Under a framework license and option agreement with DTU, Nanovi has global development and commercial rights to the platform and a first-right of refusal to related medical device inventions for use in the fields of radiotherapy and surgery.
Nanovi has co-ownership and global commercial rights to a patent-protected biomaterial technology platform for medical device inventions in the fields of radiotherapy and surgery.
Nanovi has a portfolio of 6 international families of issued patents and patent applications co-owned with DTU – The Technical University of Denmark). These patent families constitute a strong protection of the company’s technology and product rights.